ACADIA Pharmaceuticals Inc. $ACAD Holdings Trimmed by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA trimmed its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 82.7% in the third quarter, HoldingsChannel reports. The firm owned 343,086 shares of the biopharmaceutical company’s stock after selling 1,640,112 shares during the quarter. Pictet Asset Management Holding SA’s holdings in ACADIA Pharmaceuticals were worth $6,936,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. purchased a new stake in ACADIA Pharmaceuticals in the 2nd quarter valued at about $569,634,000. First Trust Advisors LP boosted its stake in shares of ACADIA Pharmaceuticals by 47.3% in the 1st quarter. First Trust Advisors LP now owns 3,343,868 shares of the biopharmaceutical company’s stock worth $74,435,000 after buying an additional 1,073,834 shares during the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of ACADIA Pharmaceuticals by 8.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 3,155,160 shares of the biopharmaceutical company’s stock worth $70,222,000 after buying an additional 234,186 shares during the last quarter. Palo Alto Investors LP purchased a new position in shares of ACADIA Pharmaceuticals in the 2nd quarter worth approximately $72,461,629. Finally, Renaissance Technologies LLC boosted its stake in shares of ACADIA Pharmaceuticals by 12.5% in the 1st quarter. Renaissance Technologies LLC now owns 1,724,196 shares of the biopharmaceutical company’s stock worth $38,381,000 after buying an additional 191,600 shares during the last quarter. 96.71% of the stock is owned by institutional investors.

ACADIA Pharmaceuticals Stock Performance

NASDAQ ACAD opened at $18.75 on Monday. ACADIA Pharmaceuticals Inc. has a 52-week low of $15.85 and a 52-week high of $30.96. The company has a 50-day simple moving average of $21.79 and a 200 day simple moving average of $23.37. The company has a market capitalization of $3.24 billion, a PE ratio of 8.89 and a beta of 0.87.

ACADIA Pharmaceuticals (NASDAQ:ACAD – Get Free Report) last announced its quarterly earnings data on Wednesday, November 4th. The biopharmaceutical company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.20 by $0.11. The business had revenue of $342.30 million for the quarter, compared to analyst estimates of $332.58 million. ACADIA Pharmaceuticals had a net margin of 30.13% and a return on equity of 8.90%. The company’s revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.42 earnings per share. As a group, analysts forecast that ACADIA Pharmaceuticals Inc. will post 0.76 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently issued reports on ACAD. Deutsche Bank reduced their target price on ACADIA Pharmaceuticals from $38.00 to $31.00 and set a “buy” rating for the company in a report on Friday, September 25th. TD Cowen reiterated a “buy” rating on shares of ACADIA Pharmaceuticals in a report on Thursday, September 24th. Wall Street Zen cut ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, November 4th. Canaccord Genuity Group boosted their price objective on ACADIA Pharmaceuticals from $36.00 to $38.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Finally, Oppenheimer restated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Wednesday, September 23rd. Thirteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $31.34.

Read Our Latest Analysis on ACADIA Pharmaceuticals

Insider Buying and Selling at ACADIA Pharmaceuticals

In other news, EVP Mark Schneyer sold 3,321 shares of the stock in a transaction that occurred on Friday, October 30th. The shares were sold at an average price of $20.88, for a total transaction of $69,342.48. Following the completion of the transaction, the executive vice president directly owned 71,322 shares of the company’s stock, valued at $1,489,203.36. This represents a 4.45% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 26.20% of the stock is owned by corporate insiders.

ACADIA Pharmaceuticals Profile

(Free Report)

ACADIA Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing medicines for neurological and rare diseases. Founded in 1993 and headquartered in San Diego, California, the company conducts research and development alongside its commercial operations. Its marketed products include NUPLAZID (pimavanserin), approved in the United States to treat hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE (trofinetide), a treatment for Rett syndrome.

Featured Stories

Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report).

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.